p30 Antibody

What are p30 antibodies and what proteins do they target?

P30 antibodies target various proteins designated as "p30" across different biological systems. Most notably, p30 is an alias for the human gene CENPV (centromere protein V), a 275-amino acid protein belonging to the Gfa family with predicted cytoplasmic and nuclear localization . In virology, p30 antibodies target viral proteins such as the p30 protein of African Swine Fever Virus (ASFV) . In parasitology, p30 refers to a major surface protein of Toxoplasma gondii that comprises 3-5% of total parasite protein and is recognized by acute and convalescent anti-toxoplasma sera .

When selecting p30 antibodies for research, it's crucial to verify which specific p30 protein your antibody targets, as cross-reactivity between different p30 proteins can lead to misleading results. Validation should include Western blotting with positive controls and, when possible, knockout/negative controls.

How are p30 antibodies typically used in research settings?

P30 antibodies serve multiple purposes in research depending on the specific p30 protein being studied:

For ASFV p30 antibodies, they are extensively used in diagnostic applications, particularly in blocking ELISA methods for detecting ASFV antibodies in serum samples . For antibodies targeting Toxoplasma gondii p30, applications include parasite surface labeling and functional studies involving parasite neutralization .

How can I develop and characterize monoclonal antibodies against p30 proteins?

Developing monoclonal antibodies against p30 proteins requires a systematic approach:

• Antigen Preparation: Express and purify recombinant p30 protein. For ASFV p30, this can be achieved by cloning the CP204L gene (582 bp) into an expression vector (e.g., pET-30a) and expressing in E. coli .

• Immunization and Hybridoma Generation: Following standard protocols, immunize mice with the purified recombinant p30, collect splenocytes, and fuse with myeloma cells to create hybridomas.

• Screening and Selection: Screen hybridoma supernatants using ELISA against recombinant p30 protein. Select positive clones for further expansion.

• Characterization:

  • Determine antibody isotype and subtype

  • Confirm specificity using Western blot against recombinant p30 and native protein

  • Perform immunofluorescence assays to verify recognition of the target in its native context

  • Assess cross-reactivity with related proteins

• Functional Characterization: For ASFV p30 antibodies, evaluate neutralizing activity and potential use in blocking ELISA development .

As demonstrated in one study, researchers generated monoclonal antibodies against ASFV p30 and characterized them using Western blot and immunofluorescence assays on infected cells. The antibody with the highest titer (mAb-2D6) was selected for developing a blocking ELISA method .

What are the known B-cell epitopes on ASFV p30 protein and how can I identify new epitopes?

Recent research has identified linear B-cell epitopes on the ASFV p30 protein that are recognized by neutralizing antibodies. To identify novel epitopes on p30, consider the following methodological approach:

• Peptide Mapping: Synthesize overlapping peptides spanning the entire p30 sequence (typically 15-20 amino acids with 5-10 amino acid overlaps).

• ELISA-Based Epitope Mapping: Coat plates with individual peptides and test reactivity with monoclonal antibodies or positive sera.

• Competitive Binding Assays: Perform competition ELISA to determine if identified peptides can block antibody binding to the full protein.

• Confirmation by Mutagenesis: Create point mutations or deletions in identified epitope regions and test for antibody binding to confirm epitope location.

• Structural Analysis: If structural data is available, map identified epitopes onto the protein structure to understand their accessibility.

In a recent study, researchers identified a novel linear and immunodominant epitope recognized by a monoclonal antibody against ASFV p30 protein . This epitope was shown to be capable of eliciting neutralizing antibodies, suggesting its potential importance for vaccine development.

How can I develop a p30-based blocking ELISA for ASFV antibody detection?

Developing a p30-based blocking ELISA for ASFV antibody detection requires careful optimization:

• Reagent Preparation:

  • Express and purify recombinant p30 protein (as coating antigen)

  • Generate and label monoclonal antibodies with horseradish peroxidase (HRP)

• Assay Protocol:

  • Coat plates with purified recombinant p30 protein (0.5 μg/ml in carbonated coating buffer, pH 9.6)

  • Block with 2% skimmed milk in PBS

  • Add test sera (diluted 1:1 in dilution buffer)

  • Add HRP-labeled anti-p30 monoclonal antibody

  • Develop with TMB substrate

  • Calculate percent inhibition (PI) using the formula: PI (%) = [(OD negative control - OD sample) / OD negative control] × 100%

• Optimization Parameters:

  • Coating antigen concentration

  • Antibody dilution

  • Sample dilution

  • Incubation times and temperatures

  • Cutoff value determination

• Validation:

  • Test known positive and negative samples

  • Calculate sensitivity and specificity

  • Perform field validation with diverse sample sets

A study demonstrated that p30 mAb-based blocking ELISA could detect seroconversion in experimentally infected pigs as early as 10 days post-infection, with increasing antibody responses detected through 20 days post-infection . The maximum dilution for ASFV-positive standard serum was 1:512, indicating high sensitivity of the assay.

What are the optimal conditions for using p30 antibodies in Western blot applications?

Optimal conditions for Western blot applications with p30 antibodies depend on the specific antibody and target system:

For ASFV p30 antibodies, Western blot analysis has successfully detected recombinant p30 protein at approximately 36 kDa . When working with Toxoplasma gondii p30, the protein migrates at an apparent molecular weight of 30 kDa on SDS-PAGE .

How can I optimize immunofluorescence assays using p30 antibodies?

Optimizing immunofluorescence assays with p30 antibodies requires attention to several critical parameters:

• Cell Fixation and Permeabilization:

  • For cytoplasmic and nuclear p30 (like CENPV): Fix cells with 4% paraformaldehyde for 15-20 minutes, followed by permeabilization with 0.1-0.5% Triton X-100 for 10-15 minutes.

  • For viral p30 in infected cells: Fix with 5% paraformaldehyde for 30 minutes, followed by permeabilization with Triton X-100 for 15 minutes .

• Blocking Conditions:

  • Use 5% serum (from the species of the secondary antibody) in PBS for 1 hour at room temperature.

• Antibody Dilution and Incubation:

  • Primary antibody: Typically 1:1000 dilution (optimize based on antibody titer), incubate for 1 hour at room temperature or overnight at 4°C.

  • Secondary antibody: Fluorophore-conjugated (e.g., FITC, Alexa Fluor) secondary antibody at 1:500-1:2000 dilution.

• Counterstaining:

  • Nuclear counterstain with DAPI (1 μg/ml) for 5-10 minutes.

• Controls:

  • Positive control: Cells known to express the target protein

  • Negative control: Uninfected cells or cells not expressing the target protein

  • Secondary antibody only control: To assess background fluorescence

In studies with ASFV p30, immunofluorescence assays successfully detected p30 protein in infected porcine alveolar macrophages (PAMs) using anti-p30 monoclonal antibodies and FITC-conjugated goat anti-mouse IgG for visualization .

How can I design experiments to evaluate the neutralizing activity of anti-p30 antibodies against viral infections?

Designing experiments to evaluate neutralizing activity of anti-p30 antibodies requires careful consideration of multiple factors:

• In Vitro Neutralization Assay:

  • Cell Selection: Choose susceptible cell lines (e.g., PK-15 cells for ASFV studies)

  • Virus Titration: Determine optimal virus concentration (typically 100-1000 TCID50)

  • Antibody Preparation: Prepare serial dilutions of purified antibodies

  • Protocol:

    • Pre-incubate virus with antibody dilutions for 1 hour at 37°C

    • Add mixture to susceptible cells

    • Incubate for appropriate time based on virus lifecycle

    • Assess infection by cytopathic effect, immunostaining, or PCR

• Readout Methods:

  • Plaque Reduction: Quantify reduction in plaque formation

  • Immunofluorescence: Detect viral antigen expression

  • qPCR: Measure viral genome replication

  • Flow Cytometry: Quantify percentage of infected cells

• Controls:

  • Positive Control: Known neutralizing antibody or positive serum

  • Negative Control: Irrelevant antibody of same isotype

  • Virus Control: Virus without antibody

  • Cell Control: Uninfected cells

• Data Analysis:

  • Calculate percent neutralization relative to virus control

  • Determine IC50 (antibody concentration giving 50% inhibition)

  • Perform statistical analysis (typically one-way ANOVA with multiple comparisons)

For ASFV p30 antibodies, studies have demonstrated their neutralizing capacity, suggesting their potential role in protective immunity and their value for vaccine development .

What approaches can be used to map the interaction between p30 antibodies and their target epitopes?

Multiple complementary approaches can be employed to map interactions between p30 antibodies and their target epitopes:

• Peptide Array Analysis:

  • Synthesize overlapping peptides (15-20 amino acids with 5-10 amino acid overlaps) spanning the p30 sequence

  • Spot peptides onto membranes or use pre-synthesized peptide arrays

  • Probe with antibodies and detect binding

  • Identify reactive peptides that contain potential epitopes

• Alanine Scanning Mutagenesis:

  • Create a series of point mutants where each amino acid in the suspected epitope region is replaced with alanine

  • Express these mutants and test antibody binding

  • Reduced binding indicates critical residues for the epitope

• Deletion and Truncation Analysis:

  • Generate a series of deletion or truncation mutants of the p30 protein

  • Test antibody binding to identify regions required for recognition

• Competition Assays:

  • Perform blocking/competition ELISA where potential epitope peptides compete with the full protein for antibody binding

  • Reduction in antibody binding to the full protein indicates successful competition by the epitope-containing peptide

• X-ray Crystallography or Cryo-EM:

  • For high-resolution mapping, determine the structure of the antibody-antigen complex

  • Identify specific contact residues and interaction characteristics

Research has successfully employed these approaches to identify linear B-cell epitopes on the ASFV p30 protein, which could serve as a basis for the development of serological diagnostic methods and subunit vaccines .

How should I interpret results from a p30-based blocking ELISA for ASFV antibody detection?

Interpreting results from a p30-based blocking ELISA requires careful analysis and consideration of multiple factors:

• Calculation of Results:

  • Calculate percent inhibition (PI) for each sample using the formula:
    PI (%) = [(OD negative control - OD sample) / OD negative control] × 100%

• Cutoff Determination:

  • Establish cutoff values using ROC curve analysis with known positive and negative samples

  • Typically, samples with PI values above the cutoff are considered positive

• Sensitivity and Specificity Considerations:

  • Assess false positive and false negative rates

  • Consider cross-reactivity with antibodies against related viruses

• Interpretation Guidelines:

  PI Value	Interpretation	Action
  PI > Cutoff + 20%	Strong Positive	Confirm with independent method
  Cutoff < PI < Cutoff + 20%	Weak Positive	Retest and confirm
  Cutoff - 10% < PI < Cutoff	Suspicious	Retest and confirm
  PI < Cutoff - 10%	Negative	No further action needed

• Time Course Considerations:

  • In experimental infections, p30 antibodies are typically detectable from 10 days post-infection, with increasing levels through 20 days post-infection

  • Absence of antibodies does not rule out early infection

• Potential Interferences:

  • Hemolyzed or lipemic samples may affect results

  • Recent vaccination may yield positive results without actual infection

The p30-based blocking ELISA has demonstrated high sensitivity, with the ability to detect ASFV-positive standard serum at dilutions up to 1:512, making it a valuable tool for field surveillance and epidemiological studies in swine herds .

What are the potential sources of variability when comparing results from different anti-p30 antibody-based assays?

When comparing results from different anti-p30 antibody-based assays, researchers should consider several potential sources of variability:

• Antibody Characteristics:

  • Specificity: Different antibodies may recognize different epitopes on p30

  • Affinity/Avidity: Higher affinity antibodies may give stronger signals

  • Clone Variability: Different monoclonal antibody clones can yield different results

  • Format: Native vs. denatured protein recognition abilities

• Assay-Specific Variables:

  • Detection Methods: Colorimetric vs. fluorescent vs. chemiluminescent detection

  • Assay Formats: Direct vs. indirect vs. sandwich vs. blocking ELISA

  • Sample Processing: Different extraction or preparation methods may affect antigen availability

• Technical Considerations:

  • Protocol Differences: Incubation times, temperatures, buffers

  • Reagent Quality: Batch-to-batch variation in antibodies or detection reagents

  • Equipment Variation: Different plate readers, microscopes, or imaging systems

• Biological Variables:

  • Strain Differences: Antigenic variation between different viral or parasite strains

  • Host Factors: Matrix effects from different sample types

  • Time Course: Different kinetics of antibody response in different individuals or studies

For example, in ASFV research, three different anti-p30 monoclonal antibodies (mAb-2D6, mAb-6B3, and mAb-10B8) showed different titers and performance characteristics in blocking ELISA development, with mAb-2D6 demonstrating the highest antibody titer and best performance in blocking assays .

How can I utilize p30 antibodies to study mutant strains of Toxoplasma gondii?

P30 antibodies offer valuable tools for studying mutant strains of Toxoplasma gondii, particularly for investigating surface antigen expression and variation:

• Selection of Antigenic Variants:

  • Use parasiticidal monoclonal anti-P30 antibodies to select resistant mutants from chemically mutagenized wild-type parasites

  • Verify mutant identity through multiple passages in the presence of selecting antibodies

  • Confirm that mutants retain sensitivity to other non-P30 parasiticidal antibodies to ensure specificity of the mutation

• Characterization of P30 Expression:

  • Surface Labeling: Compare surface radioiodinated or biotin-labeled wild-type and mutant parasites

  • Western Blot Analysis: Analyze P30 expression using anti-P30 antibodies

  • Two-Dimensional Electrophoresis: Identify specific protein variants that make up the P30 complex

• Functional Studies:

  • Invasion Assays: Compare invasion efficiency between wild-type and mutant strains

  • Antibody Neutralization Tests: Assess sensitivity to various anti-P30 antibodies

  • Host Cell Binding: Evaluate attachment to host cells

• Genetic Analysis:

  • PCR and Sequencing: Identify genetic changes in the P30 gene

  • Expression Analysis: Quantify P30 mRNA levels

  • Complementation Studies: Reintroduce wild-type P30 to confirm phenotype causation

Research has shown that mutants selected with specific monoclonal anti-P30 antibodies can show quantitative reduction in P30 expression, with some mutants lacking one or more of the proteins that comprise wild-type P30 . These findings support the hypothesis that antigenic variants of T. gondii can be induced and may involve modifications to major surface membrane antigens.